Sentrx achieves Gold Partner status in OPN

Sentrx, a leading provider of drug safety services to the life sciences industry, has achieved Gold Partner status in the Oracle PartnerNetwork (OPN). Sentrx will provide life sciences companies with support for Oracle clinical solutions, emphasizing its expertise in drug safety systems, safety data management and adverse event reporting software, processes and consulting expertise.

“Oracle's commitment to addressing healthcare and life sciences companies' need for efficient, cost effective pharmacovigilance technologies represents a tremendous opportunity for Sentrx”

The relationship brings together Oracle's leading comprehensive solutions for managing drug, device and vaccine safety with the technical, operational and strategic expertise Sentrx provides in pharmacovigilance.

"Oracle's commitment to addressing healthcare and life sciences companies' need for efficient, cost effective pharmacovigilance technologies represents a tremendous opportunity for Sentrx," said Charles Saldarini, CEO of Sentrx. "It is very exciting to be teaming with a company that fully understands the challenges our clients face in coping with complex, global requirements, data analysis and systems integration. We are very pleased to work with Oracle."